Pharming Group N.V.
Develops and commercializes medicines for rare, debilitating, and life-threatening diseases.
PHARM | AS
Overview
Corporate Details
- ISIN(s):
- NL0010391025 (+1 more)
- LEI:
- 724500DCJ9MPG74JEH91
- Country:
- Netherlands
- Address:
- Darwinweg 24, 2333CR Leiden
- Website:
- https://www.pharming.com/
- Sector:
- Manufacturing
Description
Pharming Group N.V. is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company develops and commercializes an innovative portfolio of medicines to serve patients with unmet medical needs. Its portfolio includes protein replacement therapies, precision medicines, small molecules, and biologics.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2024-04-19 07:42 |
Pharming Group announces the placement of €100 million convertible bonds due 20…
|
English | 282.7 KB | ||
| 2024-04-18 08:55 |
Pharming Group announces the launch of an offering of approximately €100 millio…
|
Dutch | 322.4 KB | ||
| 2024-04-18 08:55 |
Pharming Group announces the launch of an offering of approximately €100 millio…
|
English | 316.2 KB | ||
| 2024-04-08 07:36 |
Pharming announces completion of enrollment in pediatric clinical trial of leni…
|
Dutch | 258.5 KB | ||
| 2024-04-08 07:36 |
Pharming announces completion of enrollment in pediatric clinical trial of leni…
|
English | 262.2 KB | ||
| 2024-04-04 08:53 |
Pharming Group announces the 2024 Annual General Meeting of Shareholders
|
Dutch | 205.6 KB | ||
| 2024-04-04 08:53 |
Pharming Group announces the 2024 Annual General Meeting of Shareholders
|
English | 204.9 KB | ||
| 2024-04-04 07:44 |
Pharming Group announces the filing of its 2023 Annual Report and Form 20-F
|
Dutch | 204.2 KB | ||
| 2024-04-04 07:44 |
Pharming Group announces the filing of its 2023 Annual Report and Form 20-F
|
English | 203.0 KB | ||
| 2024-03-14 07:46 |
Pharming Group reports fourth quarter and full year 2023 financial results
|
Dutch | 576.6 KB | ||
| 2024-03-14 07:46 |
Pharming Group reports fourth quarter and full year 2023 financial results
|
English | 546.1 KB | ||
| 2024-01-08 07:33 |
Pharming Group announces updated full year 2023 guidance and Joenja® U.S. launc…
|
Dutch | 267.6 KB | ||
| 2024-01-08 07:33 |
Pharming Group announces updated full year 2023 guidance and Joenja® U.S. launc…
|
English | 262.8 KB | ||
| 2023-12-13 08:31 |
Pharming Group announces development plans for leniolisib for additional primar…
|
Dutch | 286.3 KB | ||
| 2023-12-13 08:31 |
Pharming Group announces development plans for leniolisib for additional primar…
|
English | 281.9 KB |
Automate Your Workflow. Get a real-time feed of all Pharming Group N.V. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Pharming Group N.V.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Pharming Group N.V. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-05-24 | D.A. Jorn | Non-Executive member | Other | 7,446 | N/A |
| 2023-03-21 | P. Sekhri | Non-Executive member | Other | 9,363 | N/A |
| 2022-10-27 | P. Sekhri | Non-Executive member | Buy | 13,013 | 12,232.22 EUR |
| 2022-10-27 | M. Pykett | Non-Executive member | Buy | 9,760 | 9,174.40 EUR |
| 2022-08-04 | P. Sekhri | Non-Executive member | Buy | 13,013 | 10,000.23 EUR |
| 2022-08-04 | S. Baert | Non-Executive member | Buy | 9,760 | 7,500.36 EUR |
| 2022-05-25 | J. van der Meijs | Non-Executive member | Buy | 9,300 | 86,490,000.00 EUR |
| 2022-05-25 | P. Sekhri | Non-Executive member | Buy | 12,398 | 9,527.62 EUR |
| 2022-05-25 | M. Pykett | Non-Executive member | Buy | 9,300 | 7,146.86 EUR |
| 2022-03-24 | S. de Vries | Non-Executive member | Buy | 318,150 | 232,249.50 EUR |
Peer Companies
